SGHT vs. CLPT, SIBN, BVS, AVNS, ZIMV, BFLY, KIDS, TMCI, SMLR, and CBLL
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include ClearPoint Neuro (CLPT), SiBone (SIBN), Bioventus (BVS), AVANOS MEDICAL (AVNS), ZimVie (ZIMV), Butterfly Network (BFLY), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), Semler Scientific (SMLR), and CeriBell (CBLL). These companies are all part of the "medical equipment" industry.
Sight Sciences vs. Its Competitors
Sight Sciences (NASDAQ:SGHT) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
Sight Sciences currently has a consensus target price of $4.42, suggesting a potential upside of 34.25%. ClearPoint Neuro has a consensus target price of $19.67, suggesting a potential downside of 28.17%. Given Sight Sciences' higher probable upside, research analysts plainly believe Sight Sciences is more favorable than ClearPoint Neuro.
55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 30.9% of Sight Sciences shares are owned by company insiders. Comparatively, 6.1% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Sight Sciences had 5 more articles in the media than ClearPoint Neuro. MarketBeat recorded 10 mentions for Sight Sciences and 5 mentions for ClearPoint Neuro. Sight Sciences' average media sentiment score of 0.60 beat ClearPoint Neuro's score of 0.26 indicating that Sight Sciences is being referred to more favorably in the media.
Sight Sciences has a net margin of -64.23% compared to ClearPoint Neuro's net margin of -66.15%. Sight Sciences' return on equity of -59.38% beat ClearPoint Neuro's return on equity.
ClearPoint Neuro has lower revenue, but higher earnings than Sight Sciences. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.
Sight Sciences has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
Summary
Sight Sciences beats ClearPoint Neuro on 11 of the 15 factors compared between the two stocks.
Get Sight Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:SGHT) was last updated on 10/6/2025 by MarketBeat.com Staff
